Tanox, Inc. (de, USA)
Records under this name other than patents Tanox, Inc. (de, USA) holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,927,592 | Method of Inhibiting Complement Activation Formerly held Lapsed on the fee record Ended Apr 19, 2023 · High confidence | Lapsed on the fee record | Ended Apr 19, 2023 | High confidence |
| US 6,998,468 | ANTI-C2/C2A Inhibitors of Complement Activation Formerly held Term ended Term ended Nov 21, 2022 · High confidence | Term ended | Term ended Nov 21, 2022 | High confidence |
| US 6,534,058 | ANTI-C5 Monoclonal Antibodies Formerly held Term ended Term ended Oct 4, 2021 · High confidence | Term ended | Term ended Oct 4, 2021 | High confidence |
| US 7,432,356 | Complement Pathway Inhibitors Binding to C5 and C5A Without Preventing Formation of C5B Formerly held Lapsed on the fee record Ended Oct 7, 2020 · High confidence | Lapsed on the fee record | Ended Oct 7, 2020 | High confidence |
| US 7,118,743 | Bispecific Molecules Cross-Linking Itim and Itam for Therapy Formerly held Term ended Term ended Nov 17, 2019 · Medium confidence | Term ended | Term ended Nov 17, 2019 | Medium confidence |
| US 6,956,107 | Inhibitors of Complement Activation Formerly held Term ended Term ended Feb 20, 2019 · Medium confidence | Term ended | Term ended Feb 20, 2019 | Medium confidence |
| US 7,112,327 | Inhibition of Complement Activation Formerly held Term ended Term ended Feb 20, 2019 · Medium confidence | Term ended | Term ended Feb 20, 2019 | Medium confidence |
| US 7,439,331 | Inhibition of Complement Activation Formerly held Term ended Term ended Feb 20, 2019 · Medium confidence | Term ended | Term ended Feb 20, 2019 | Medium confidence |
| US 7,943,135 | Method of Treatment Using Anti-Factor D Antibodies Formerly held Term ended Term ended Feb 20, 2019 · Medium confidence | Term ended | Term ended Feb 20, 2019 | Medium confidence |
| US 6,657,050 | Chimeric viral-neutralizing immunoglobulins Formerly held Lapsed on the fee record Ended Dec 2, 2015 · USPTO record | Lapsed on the fee record | Ended Dec 2, 2015 | USPTO record |